Appili Therapeutics Inc.
APLIF
$0.0272
$0.00124.62%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -54.82% | -77.61% | -77.61% | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -54.82% | -77.61% | -77.61% | -100.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -54.82% | -77.61% | -77.61% | -100.00% |
| SG&A Expenses | -16.02% | 2.26% | -1.56% | -9.05% | -20.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.96% | -13.20% | -59.15% | -68.35% | -73.22% |
| Operating Income | 0.65% | 6.68% | 57.80% | 67.83% | 71.89% |
| Income Before Tax | 48.67% | 31.04% | 60.46% | 65.34% | 64.32% |
| Income Tax Expenses | 133.49% | 1,763.16% | 26.24% | -13.23% | -31.31% |
| Earnings from Continuing Operations | 48.16% | 30.21% | 60.34% | 65.26% | 64.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 48.16% | 30.21% | 60.34% | 65.26% | 64.27% |
| EBIT | 0.65% | 6.68% | 57.80% | 67.83% | 71.89% |
| EBITDA | 0.69% | 6.69% | 57.82% | 67.84% | 71.91% |
| EPS Basic | 60.86% | 54.27% | 77.86% | 79.86% | 75.23% |
| Normalized Basic EPS | 58.30% | 52.54% | 77.01% | 79.25% | 75.32% |
| EPS Diluted | 60.86% | 54.27% | 77.86% | 79.86% | 75.23% |
| Normalized Diluted EPS | 58.30% | 52.54% | 77.01% | 79.25% | 75.32% |
| Average Basic Shares Outstanding | 19.81% | 37.15% | 64.31% | 70.37% | 56.69% |
| Average Diluted Shares Outstanding | 19.81% | 37.15% | 64.31% | 70.37% | 56.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
